Advertisement

Picture Fairtec GmbH Worldwide Event Solutions 600x60px
Document › Details

Pharmanest AB. (5/18/18). "Press Release: Helena Jansson Appointed as New CEO of Pharmanest".

Organisations Organisation Pharmanest AB
  Organisation 2 Medivir AB (Nasdaq Stockholm: MVIR)
  Today Medivir (Group)
  Group Medivir (Group)
Products Product pain drug
  Product 2 women’s health
Person Person Jansson, Helena (Pharmanest 201805– CEO before Medivir since 2000)
     


The Board of Pharmanest AB, a Swedish private pharmaceutical company, has appointed Helena Janson to the new CEO of the company. She is replacing Gunilla Lundmark who leaves her position after seven years. Helena Jansson comes recently from leading positions in Medivir (including the subsidiary BioPhausia) a Swedish public pharmaceutical company where she has been employed since 2000. Helena has long experience in the life science industry and a broad knowledge base with a focus on business development and commercialisation of pharmaceutical portfolios.

”The appointment of Helena Jansson to Pharmanest’s new CEO means that the company now has a leader onboard with a very strong background to take a drug from the R&D phase to the marketing and sales phase. I am delighted to welcome Helena to our company. Her broad industry competence and experience will strengthen the company’s scientific and commercial position. I also would like to thank Gunilla Lundmark for valuable contribution to Pharma under her leadership and wish her the best in future challenges, says Håkan Wallin, chairman of Pharmanest.

Pharmanest passed an important business milestone during the latter part of 2017 when the company signed an outlicensing agreement with Gedeon Richter, a leading European pharmaceutical company within women’s health. The agreement gives Gedeon Richter the marketing and sales rights to commercialise Pharmanest’s first product SHACT (Short Acting Lidocaine) in Europe, in Latin America and in certain other markets. SHACT is a patented and proprietary formulation of lidocaine for mucosal topical pain relief where the lead indication is the treatment of pain during intrauterine device (“IUD”) placement.


For further information:
Håkan Wallin, Chairman of the Board of Directors, Pharmanest AB
Tel: +46 708 206 594
E-mail: hakan.vallin@telia.com

Helena Jansson, new CEO, Pharmanest AB
Tel: +46 70 879 77 96
E-mail: helena.jansson@pharmanest.se

   
Record changed: 2018-05-23

Advertisement

Picture BioM Forum Translational Medicine 2018 Würzburg Germany 600x60px

More documents for Pharmanest AB


To subscribe to our free, monthly newsletter for the European life sciences, please send an e-mail to info@iito.de and simply fill the subject line with the word »LSE Newsletter«

To get even more information, please take a look at our [gs] professional services offering and read the gene-sensor Product Flyer [PDF file]

Advertisement

Picture BioM Forum Translational Medicine 2018 Würzburg Germany 600x60px




» top